Proton NMR spectroscopy of cerebral metabolic alterations in infantile peroxisomal disorders.
Noninvasive studies of cerebral metabolism were performed with use of localized proton MR spectroscopy (MRS) in both healthy controls (n = 4, age 6 weeks to 2 years) and infants (n = 4, age 3-15 months) who had impaired peroxisomal functions classified as variants of Zellweger syndrome. All patients revealed a marked decrease of N-acetylaspartate in white and gray matter, thalamus, and cerebellum, indicating impairment of normal neuronal development as well as neuronal loss. In two cases an increase of cerebral glutamine and a decrease of the cytosolic polyol myo-inositol in gray matter and striatum reflected the impact of a concomitant effect on hepatic function. Two cases 3 and 6 months of age exhibited a notable elevation of mobile lipids and/or cholesterol in white matter. These patients with severe disease died within 4 weeks after the MRS examination. While an increase of free fatty acids generally associated with a lysosomal storage disease was not consistently observed by proton MRS of brain, this technique provides a convenient and safe tool for the direct assessment of neuropathologic aspects of Zellweger syndrome such as neuronal degeneration, demyelination, and consequences of compromised liver function.
Bruhn
H
H
Max-Planck-Institut für biophysikalische Chemie, Göttingen, Germany.
Kruse
B
B
Korenke
G C
GC
Hanefeld
F
F
Hänicke
W
W
Merboldt
K D
KD
Frahm
J
J
D000326:Adrenoleukodystrophy / Q000378:metabolism*; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D001921:Brain / Q000378:metabolism*; D005260:Female; D005973:Glutamine / Q000378:metabolism; D006801:Humans; D007223:Infant; D007294:Inositol / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D015211:Zellweger Syndrome / Q000378:metabolism*
D005973:Glutamine; D001224:Aspartic Acid; D007294:Inositol; C000179:N-acetylaspartate